[Morning session on the first day of the 2026 State Talks: Negotiations on a variety of traditional Chinese medicines began. Representatives from China Resources Sanjiu, Kangyuan Pharmaceutical and other companies entered the venue] On September 5, reporters learned from the on-site negotiations on the 2026 National Medical Insurance Catalog and the Price Negotiation on the Commercial Insurance Innovative Drug List that at around 8 a.m. on the first day of the State Talks today, corporate negotiators had lined up outside the venue and began to enter the venue one after another. Traditional Chinese medicine companies including Kangyuan Pharmaceutical, Kangpu Pharmaceutical, China Resources Sanjiu, Qidu Pharmaceutical, etc. were the first to enter the market. In addition, Zai Lab, North China Pharmaceutical, Genting Xinyao, Qilu Pharmaceutical, China Medical System, and Joincare were present in the morning session. The reporter learned that this year’s national talks include a large number of key traditional Chinese medicine varieties. Guangyuyuan Banxia Xiexin Tang Granules, Tasly Zaoren Ningxin Dropping Pills, and Kangyuan Pharmaceutical Shenpu Granules all passed the preliminary review. (Reporter Lu Afeng)